Search Result

Results for "

3,4-Dihydroxyphenylalanine

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) Dopamine Receptor (5) Endogenous Metabolite (5) Endothelin Receptor (1) Liposome (2)
By Research Areas:	Cancer (4) Cardiovascular Disease (1) Infection (1) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0304

L-DOPA 15+ Cited Publications Levodopa; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304S

L-DOPA-d6 Levodopa-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304S1

L-DOPA-13C6 Levodopa-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-131678

Palmitoyl serotonin PA-5HT	Others	Neurological Disease
Palmitoyl serotonin is a hybrid molecule patterned after arachidonoyl serotonin, antagonist of FAAH. Palmitoyl serotonin inhibits L-3,4-dihydroxyphenylalanine (HY-N0304) induced abnormal involuntary movements. Palmitoyl serotonin has the potential for the research of parkinson's disease (PD) .

HY-P3100

Orfamide A	Liposome	Cancer
Orfamide A is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-P3350

LS-BF1	Bacterial	Infection
LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].

HY-P10447

Plipastatin A1 Fengycin IX; SNA-60-367-3	Liposome	Cancer
Plipastatin A1 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

Cat. No.	Product Name	Target	Research Area

HY-P4755

*N-((RS)-2-Hydroxy-propyl)-Val-Leu-anilide*	Peptides	Others
N-((RS)-2-Hydroxy-propyl)-Val-Leu-anilide is a polypeptide that can be found by peptide screening. Peptide screening is a research tool that pools active peptides primarily by immunoassay. Peptide screening can be used for protein interaction, functional analysis, epitope screening, especially in the field of agent research and development .

HY-P3100

Orfamide A	Liposome	Cancer
Orfamide A is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-158104

LPPM-8	Peptides	Others
LPPM-8 is a ligand of Med25 and an inhibitor of Med25 protein-protein interactions (PPIs). LPPM-8 engages Med25 through interaction with the H2 face of its Activator Interaction Domain and stabilizes full-length protein in the cellular proteome. LPPM-8 is an orthosteric inhibitor of H2-binding transcriptional activators (such as ATF6a). LPPM-8 can be used for studying Med25 and Mediator complex biology .

HY-P3350

LS-BF1	Bacterial	Infection
LS-BF1 is a stable and low toxic cationic antimicrobial peptide. LS-BF1 displays broad spectrum of antibacterial activity, including the challenging ESKAPE pathogens, by cell membrane disruptive mechanism. LS-BF1 shows good in vivo efficacy for elimination of bacteria in a mouse infection model[1].

HY-P10447

Plipastatin A1 Fengycin IX; SNA-60-367-3	Liposome	Cancer
Plipastatin A1 is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .

HY-105168

TAK 044	Endothelin Receptor	Cardiovascular Disease
TAK 044 is an antagonist of Endothelin Receptor. TAK 044 strongly inhibits ET-induced deterioration in various animal models. TAK 044 can be used in study ET-related diseases such as acute myocardial infarction,acute renal failure, acute hepatic malfunction, and subarachnoid hemorrhage .

HY-125357

Ternatin	Peptides	Metabolic Disease
Ternatin (compound 2) is a cyclic heptapeptides that can be isolated from mushroom Coliorus versicolor. Ternatin inhibits fat-accumulation with an IC₅₀ of 0.027 μM in 3T3-L1 adipocytes .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0304

L-DOPA 15+ Cited Publications Levodopa; 3,4-Dihydroxyphenylalanine	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-N0304A

L-DOPA sodium Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Phenols Polyphenols Endogenous metabolite Disease Research Fields	Dopamine Receptor Endogenous Metabolite
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

L-DOPA (Standard) Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Ketones, Aldehydes, Acids Disease markers Phenols Polyphenols Nervous System Disorder Endogenous metabolite	Dopamine Receptor Endogenous Metabolite
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

Cat. No.	Product Name	Chemical Structure

HY-N0304S

L-DOPA-d6
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-N0304S1

L-DOPA-13C6
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

3,4-Dihydroxyphenylalanine

Inhibitors & Agonists

Peptides

NaturalProducts

Isotope-Labeled Compounds

Natural
Products